While a recent study demonstrated superior in vitro activity of the dual PI-3K/mTOR inhibitors over mTOR inhibition alone in ALL in vitro [21], we extended these findings to the in vivo setting using a human ALL xenograft model in NOD/SCID mice. Here, MTOR is linked to acute lymphoblastic leukemia.